Tag: GlobeNewswire

AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlement and anchoring to Ethereum

MATAWAN, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) — via IBN – MindWave Innovations Inc. USA (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 2-year master maintenance and service agreement with Delaware-based BlockAssure Inc. (“BlockAssure”) to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure’s insurance and reinsurance operations on-chain.

For MindWave, this is an important expansion of its U.S. business. It takes the company’s technology work into insurance and reinsurance, and it is a long-term build-and-operate contract with a U.S. client.

“BlockAssure chose us to build AssureChain, and it is exactly the kind of work we want to do for U.S. clients,” said Dr. Vin Menon, Chief Executive Officer of MindWave Innovations Inc. USA.

MindWave will design, develop, security-audit and deploy AssureChain, then host, operate and maintain it once it goes live. All of BlockAssure’s insurance work will happen on AssureChain: contracts, policies, premium and payment entries, reinsurance treaties and claims processing, from the start of a policy to the settlement of a claim. MindChain’s job is narrower – It provides the settlement layer and anchors AssureChain’s records to Ethereum.

MindWave will earn contracted development fees, payable in quarterly installments, with later operating and maintenance fees to be agreed. The agreement also provides for an allocation to MindWave equal to 20% of the total supply of AssureCoin, a digital token BlockAssure plans to create within the MindChain network, delivered when the token is created. The allocation is fully vested on delivery, and anti-dilution terms maintain MindWave’s 20% share if additional AssureCoin is issued during the term or for two years afterward.

The aim is straightforward: BlockAssure handles the market relationships, and MindWave builds and runs the network underneath them. Contracts, policies, payments, treaties and claims all run on AssureChain. Because it settles through MindChain and anchors to Ethereum, you can follow any claim from the policy that created it to the recovery that closes it outFor the length of the agreement, MindWave is BlockAssure’s exclusive blockchain provider for AssureChain.

The two companies have divided the work along clear lines. BlockAssure will lead underwriting and claims decisions, licensing, and its relationships with insurers, reinsurers and brokers. MindWave supplies the infrastructure and the technical services needed to run AssureChain. It acts only as the technology provider.

AssureChain is made up of four modules and a data oracle: insurance contracts; policy issuance and lifecycle management, including premium and payment entries; reinsurance treaties and facultative placements; and claims processing from notification through assessment, settlement and reinsurance recovery. The oracle feeds verified parametric, environmental, catastrophe, market and identity data onto AssureChain, which lets a parametric claim trigger automatically once a pre-agreed threshold is met.

Each claim on AssureChain can be traced back to the policy, contract and treaty it came from, and MindChain anchors those records to Ethereum. BlockAssure and its counterparties therefore work from one verifiable record, from placement to settlement. Each module will be independently security-audited before production, and personal data will not be written on-chain except in hashed or tokenized form.

The agreement took effect on Oct. 4, 2026. Development is planned over four quarters against agreed milestones, and BlockAssure will acceptance-test each module. Once the first module is accepted, MindWave takes on hosting, validator operations, maintenance, security patches and helpdesk support.

After the initial 2-year term, the agreement renews automatically for one-year periods unless either party gives 90 days’ notice.

About MindWave Innovations Inc. USA
MindWave Innovations Inc. USA, a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), develops technology infrastructure and digital solutions for blockchain-enabled applications, data-driven platforms, and emerging commercial ecosystems.

Through projects such as AssureChain, MindWave is expanding the application of its technology into insurance, reinsurance and digital-asset-enabled insurance models.

For more information, visit https://www.mindwaveinnovations.com/

About MindChain
MindChain is a blockchain infrastructure developed within the MindWave ecosystem to support transparent, traceable, and verifiable digital transactions. It is designed to provide the underlying ledger capabilities required for applications involving digital assets, registries, tokenized ecosystems, and decentralized services.

About AssureChain
AssureChain is BlockAssure’s dedicated insurance and reinsurance network and runs as a subnet of MindChain. Every insurance function runs on AssureChain. MindChain handles settlement and anchoring to Ethereum.

About BlockAssure Inc.
BlockAssure Inc. is a Delaware corporation developing an insurance and reinsurance platform supported by digital asset capital.

For more information, visit https://www.blockassure.io/

Forward-Looking Statements
This announcement contains forward-looking statements regarding the development, implementation, anticipated capabilities, and potential performance of AssureChain, and the potential creation and allocation of AssureCoin. These statements are based on current expectations and are subject to risks and uncertainties, including development timelines, achievement of project milestones, technical performance, regulatory requirements, BlockAssure’s licensing, whether and when AssureCoin is created, and market acceptance. Actual results may differ materially from those expressed or implied. The company undertakes no obligation to update these statements except as required by applicable law.

Media and Investor Relations
MindWave Innovations Inc. USA
Website : https://www.mindwaveinnovations.com
Email : contact@mindwaveinnovations.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

STMicroelectronics announces status
of common share repurchase program

Disclosure of Transactions in Own Shares – Period from September 28, 2026 to October 2, 2026

AMSTERDAM – October 05, 2026 — STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder resolution dated May 22, 2024 and by the supervisory board.

STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris, in the period between September 28, 2026 to October 2, 2026 (the “Period”), of 310,000 ordinary shares (equal to 0.03% of its issued share capital) at the weighted average purchase price per share of EUR 47.1205 and for an overall price of EUR    14,607,365.00.

The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from share option programmes, or other allocations of shares, to employees or to members of the administrative, management or supervisory bodies of the issuer or of an associate company.

The shares may be held in treasury prior to being used for such purpose and, to the extent that they are not ultimately needed for such purpose, they may be used for any other lawful purpose under article 5(2) of the Market Abuse Regulation.

Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

 Transactions in Period

Dates of transaction	Number of shares purchased	Weighted average purchase price per share (EUR)	Total amount paid (EUR)	Market on which the shares were bought (MIC code)
28-Sep-26	70,000	45.5195	3,186,365.00	XPAR
29-Sep-26	60,000	47.2025	2,832,150.00	XPAR
30-Sep-26	60,000	46.8866	2,813,196.00	XPAR
1-Oct-26	60,000	47.0945	2,825,670.00	XPAR
2-Oct-26	60,000	49.1664	2,949,984.00	XPAR
Total for Period	310,000	47.1205	14,607,365.00

Following the share buybacks detailed above, the Company holds in total 15,583,565 treasury shares, which represents approximately 1.7% of the Company’s issued share capital.

In accordance with Article 5(1)(b) of the Market Abuse Regulation and Article 2(3) of Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual trades in the Program are disclosed on the ST website (https://investors.st.com/stock-and-bond-information/share-buyback).

About STMicroelectronics
At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com   

For more information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
jerome.ramel@st.com    
  
MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
alexis.breton@st.com

Attachment

• C3414C — Oct 5 2026 — Disclosure of transactions in Own Shares PR_FINAL FOR PUBLICATION

ORION CORPORATION
PRESS RELEASE
05 OCTOBER 2026 at 8:00am ET

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing 
Milestone marks Orion Pharma’s entry into clinical-stage biologics (large molecules) and advances the company’s immuno-oncology portfolio

ESPOO, Finland, CAMBRIDGE, United Kingdom and CAMBRIDGE, M.A., October 5, 2026 – Orion Corporation (Orion Pharma) today announced that the first patient has been dosed in the BICIDES Phase 1/2 clinical trial evaluating the safety, pharmacokinetics and preliminary anti-tumor activity of ODM-216, an investigational bispecific antibody simultaneously targeting PVRIG and PD-L1 in patients with advanced solid tumors. ODM-216 is Orion Pharma’s first biologic candidate and first immuno-oncology treatment to enter clinical testing in humans. ODM-216 is a key component of Orion Pharma’s immuno-oncology portfolio, including several assets in the pre-clinical pipeline.

“Treating the first patient in the ODM-216 BICIDES study is a significant achievement for Orion Pharma and an important moment in the evolution of our long-term global R&D strategy to expand our capabilities beyond small molecules and into biologics,” said Professor Outi Vaarala, M.D., Ph.D., Executive Vice President, Research & Development at Orion Pharma. “As both our first biologic and first immuno-oncology candidate to reach clinical stage, ODM-216 reflects our team’s commitment to discovering and advancing innovative new treatment approaches that further strengthen our foundation for a diversified future oncology pipeline. We look forward to evaluating ODM-216 in the clinic as we continue our mission for people living with difficult-to-treat cancers.”

ODM-216’s advancement is fueled by Orion Pharma’s internal research & development efforts across its global R&D organization located in Finland, the UK and the US, including the company’s Biologics Research & Development Centre in Cambridge, UK, which was established in 2025 to strengthen Orion Pharma’s biologics capabilities.

The Phase 1/2 trial is known as BICIDES and more information can be found on ClinicalTrials.gov using identifier: NCT07805252.

About ODM-216
ODM-216 is an investigational anticancer medicine being developed by Orion Pharma. Designed to activate anti-tumor immune responses, ODM-216 is a bispecific antibody simultaneously targeting PVRIG and PD-L1, two immune-regulatory pathways involved in cancer growth and progression.

Media contact:
Maddie Davidshofer, Lead, Scientific & Pipeline Communications
tel. +1 857 529 0169

Investor contact:
Tuukka Hirvonen, Head of Investor Relations
tel. +358 10 426 2721                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development.

Source: Oncotelic Therapeutics, Inc.

AGOURA HILLS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), together with its wholly owned subsidiary Pet2DAO, Inc. (“Pet2DAO”), today announced that PDAOAI, the Company’s AI-powered drug discovery platform, is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. The invitation accompanies two keynote presentations at Drug Discovery 2026, including a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation can generate testable research hypotheses.

BIO REBOOT Opens Registration

Through BIO REBOOT, individuals and teams can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community. Registration is free at https://pdaoai.com/bio-reboot.

Selected projects may be considered for startup funding and Oncotelic support spanning validation, formulation, regulatory planning and clinical development. Funding, platform access and development support are subject to scientific review, available resources and agreed terms.

“We’re excited about the discoveries we’re making with PDAOAI, and we’re opening the door for others to build with us,” said Saran Saund, Chief Business Officer of Oncotelic. “Our hepatocellular carcinoma case study is one example: PDAOAI helped identify a candidate four-gene signature, opening a new direction for research. Through BIO REBOOT, we want to help collaborators turn promising ideas into discoveries that can be tested and developed.”

“Researchers need a faster, more practical way to move from a broad question to a set of relevant papers they can inspect and discuss,” said Scott Myers, Product Manager at Oncotelic. “Our focus with PDAOAI is helping them find relevant material, understand the sources behind an answer and decide what question deserves further investigation.”

Drug Discovery 2026 Presentations

Saran Saund, Chief Business Officer, and Scott Myers, Product Manager, will deliver keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place October 7–9, 2026, at the Hilton San Francisco Airport Bayfront in Burlingame, California. Saund will also participate in a panel discussion on October 8.

The conference brings together pharmaceutical and biotechnology professionals, academic researchers and drug development specialists to discuss advances in drug discovery and lead optimization. The organizer lists speakers from Amgen, Eli Lilly and Company, the National Institutes of Health, Harvard Medical School and Stanford University.

Saran Saund — Thursday, October 8, 2026, 10:00–10:30 a.m. Pacific Time

Partitioning 4.4 million Abstracts by Disease Turns a Literature Review into a Discovery: A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population

Scott Myers — Wednesday, October 7, 2026, 11:20–11:50 a.m. Pacific Time

The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development

Panel Discussion

On October 8, Saund will also join the panel discussion titled “The Future of Drug Discovery: Integrating AI, Innovative Technologies, and Multidisciplinary Research.” The session will address the role of AI and collaboration across disciplines in the next generation of drug discovery.

About PDAOAI and Pet2DAO

PDAOAI is an AI-powered drug discovery platform developed by Oncotelic Therapeutics, Inc. (OTCQB: OTLC). Oncotelic and its wholly owned subsidiary, Pet2DAO, Inc., support the BIO REBOOT collaboration initiative. Built on a current index of 29 million PubMed abstracts, PDAOAI maps biomedical literature into a high-dimensional vector space and applies mathematical algorithms to uncover relationships across genes, pathways and diseases. Its Partitioned Literature Aggregation (PLA) method analyzes disease-specific literature groups separately before combining the findings, helping limit the influence of differences in publication volume. By connecting evidence scattered across decades of research, PDAOAI surfaces candidate drug targets and testable hypotheses for drug discovery, repurposing and therapeutic development, with evidence traceable to source publications. For more information, visit www.pdaoai.com.

About Oncotelic

Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The Company also develops the PDAOAI platform to support its work in drug discovery and development. Additional information is available at www.oncotelic.com.

Oncotelic’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “estimate” and “will” can identify forward-looking statements. Forward-looking statements in this release include statements regarding the Company’s anticipated conference participation, planned presentations and panel discussion, the development and use of PDAOAI and PLA, and their potential to support hypothesis generation and further scientific investigation. Forward-looking statements also include plans for BIO REBOOT collaborations and potential startup funding, platform access and drug development support. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive. The Company faces known and unknown risks, including the risk factors described in the Company’s 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026 and in the Company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the Company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.

Contact Information
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
BIO REBOOT collaboration inquiries: Scott Myers, scott.myers@oncotelic.com

Field crews demobilizing following completion of geological mapping, prospecting and soil and rock sampling

CALGARY, Alberta, Oct. 05, 2026 (GLOBE NEWSWIRE) — Northern Discovery Metals Inc. (CSE: NOR) (FSE: M1V0) (“Northern Discovery” or the “Company”) is pleased to announce that Stage 1 fieldwork at the Vent Copper Project (“Vent” or the “Project”) is complete and field crews are demobilizing. The Project is located in the Alberni Mining Division on Vancouver Island, British Columbia, where the Company holds an option to acquire up to a 100% interest.

The program was carried out by Geomap Exploration Inc. and included geological mapping, prospecting, and soil and rock sampling. Building on the progress reported in the Company’s September 22, 2026 news release, the work was designed to improve the geological understanding of priority areas and assess the relationships between geochemical responses, geological contacts, structures, alteration and veining.

“With the fieldwork complete, our focus turns to evaluating the results and determining where to concentrate further exploration,” said Jared Suchan, Ph.D., P.Geo., Chief Executive Officer of Northern Discovery Metals. “Bringing the new mapping and sampling together with our existing geophysical information will help us assess which areas warrant more detailed investigation and what work is needed to advance them.”

The Company plans to integrate the field observations and laboratory results, following review and validation, with its existing geological, geochemical and airborne magnetic and VLF-EM datasets. This work will support refinement of the geological model and the ranking of areas for follow-up. Depending on the results, subsequent exploration may include focused induced polarization surveys or other ground geophysical work. The scope and timing of further fieldwork will be determined after evaluation of the Stage 1 results. No analytical results from the program are reported in this release. The Company intends to provide a further update following receipt and review of the results.

Qualified Person Statement

Jared Suchan, Ph.D., P.Geo., Chief Executive Officer and Director of the Company, and a “Qualified Person” within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical contents of this news release.

For a further discussion of the Company’s QA/QC and data verification procedures and processes, please see the technical report entitled, Technical Report on the Vent Copper Property, Alberni Mining Division, British Columbia, Canada, NTS Map 092F03W,” dated July 22, 2026, a copy of which may be obtained under the Company’s profile at www.sedarplus.ca.The Property is an exploration-stage mineral property with no current mineral resource or mineral reserve estimates.

About Northern Discovery Metals Inc.

Northern Discovery Metals Inc. is a mineral exploration company focused on the acquisition, exploration and advancement of mineral properties in Canada. The Company is exploring for copper at its Vent Project on Vancouver Island, British Columbia. Northern Discovery Metals intends to advance the Project through systematic exploration and evaluation of its mineral potential.

On Behalf of the Board of Directors

Jared Suchan

Chief Executive Officer and Director

Phone: (604) 294-3020

Email: info@northerndiscoverymetals.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled”, “targeted”, “may”, “will”, “could”, “would” and similar expressions, or statements that certain events or conditions “will”, “may” or “could” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the expected timing, duration, scope and focus of the exploration program at the Property; the evaluation and follow-up of geochemical responses, magnetic and VLF-EM responses and other evidence encountered during the program; the integration of program results with existing geological, geochemical and geophysical information; the refinement of the Company’s geological model and ranking of priority areas; the potential identification of coherent geological and geochemical targets; the possible undertaking of focused induced-polarization or other ground geophysical work; the potential refinement and ranking of drill targets; and the Company’s plans to systematically explore, evaluate and advance the Property. 

Forward-looking statements are based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the availability of personnel, contractors, equipment, supplies and financing on acceptable terms; the accuracy, reliability and completeness of historical and existing geological, geochemical and geophysical data; the ability to obtain and maintain all required permits, approvals and access arrangements; suitable weather, access and field conditions; and the absence of material adverse changes in applicable laws, commodity prices, market conditions or the Company’s business and financial position. Although the Company considers these assumptions reasonable based on information currently available, they may prove to be incorrect. 

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date hereof, and the Company undertakes no obligation to update or revise them to reflect new events or circumstances, except as required by applicable securities laws. 

The CSE has neither approved nor disapproved the information contained herein.

MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., is pleased to announce an expansion of its long-term international supply agreement (the “Agreement”) with Curaleaf International Limited (“Curaleaf”), previously announced on July 14, 2026. If fully realized, the amended Agreement has a potential aggregate contract value of approximately C$34 million over its two-year term, compared with up to C$21 million under the original Agreement, based on committed supply volumes and the terms and conditions of the Agreement. The expanded relationship builds on Cannara’s first long-term international supply commitment and provides an opportunity to grow international sales through Curaleaf’s established distribution network while continuing to support the Company’s Canadian growth strategy.

“The expansion of our agreement reflects the strong relationship we are building with Curaleaf and the quality of the cannabis we have supplied from our Valleyfield facility,” said Zohar Krivorot, Founder and Chief Executive Officer of Cannara. “We see a meaningful opportunity to grow together as partners, supplying Québec-grown cannabis to international medical markets while continuing to execute our growth strategy here in Canada.”

“This expanded agreement demonstrates our ability to grow within the cultivation infrastructure we already own at Valleyfield, where we now have 15 of our 24 grow rooms active,” said Niko Sosiak, Chief Operating Officer of Cannara. “With a fully funded build-out plan, our remaining capacity gives us a clear runway to scale production as demand grows, while maintaining consistent quality and the cost discipline that support our growth in Canada and internationally.”

Curaleaf also continues to support Cannara’s pursuit of EU-GMP certification for its processing center at Valleyfield. In the interim, cannabis flower supplied under the Agreement will be dried and processed under EU-GMP conditions at Curaleaf’s EU-GMP certified facility in Canada before release into international medical markets.

CONTACT

Scott Carroll, PhD, MBA
Vice President, Investor Relations & Commercial Strategy
scott.carroll@cannara.ca

ABOUT CANNARA

Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products. Cannara owns two mega facilities based in Québec spanning over 1,600,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s favourable energy costs, Cannara maintains an efficient, low-cost production model. For more information, please visit cannara.ca.

ABOUT CURALEAF

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. Curaleaf International’s unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. For more information, please visit ir.curaleaf.com

CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION

This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, statements regarding the anticipated benefits of the amended Agreement, the timing and extent of the increased cultivation allocation, expected plant volumes and supply of cannabis flower, the potential aggregate contract value and the extent to which it is realized, anticipated international sales and Canadian growth, the parties’ performance of their respective obligations, the pursuit and potential receipt of EU-GMP certification and future dried-flower pricing.

In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.

Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
28-Sep-26	50,000	€1,529.45	€76,472,475
29-Sep-26	57,000	€1,596.29	€90,988,564
30-Sep-26	50,000	€1,609.32	€80,466,190
1-Oct-26	60,000	€1,602.84	€96,170,670
2-Oct-26	60,000	€1,639.73	€98,384,082

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts Monique Mols, phone +31 6 528 444 18

Investor Relations contacts Jim Kavanagh, phone +31 40 268 3938 Pete Convertito, phone +1 203 919 1714 Peter Cheang, phone +886 3 659 6771

        

Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging

Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in next 30 days

SYDNEY, Oct. 05, 2026 (GLOBE NEWSWIRE) — Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage radiopharmaceutical company, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA or the Agency) regarding RAD101, the Company’s investigational radiopharmaceutical imaging agent for the detection of brain metastases.

RAD101 is the Company’s novel Fluorine-18-labeled small-molecule imaging agent that targets fatty acid synthase (FASN) and is being developed to diagnose suspected recurrent brain metastases arising from a range of solid tumors. Previously reported data from the Phase 2b clinical trial showed that RAD101 demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial’s primary endpoint.

The Company expects to receive the FDA’s official meeting minutes within approximately 30 days. The minutes will provide the formal record of the meeting and the Agency’s feedback on the proposed pivotal clinical development program. RAD intends to provide a further update following receipt and review of the official minutes.

“The successful completion of our End-of-Phase 2 meeting with the FDA marks a pivotal milestone for RAD101 and an important inflection point in the evolution of our company,” said Riccardo Canevari, Chief Executive Officer of Radiopharm. “The discussion was highly constructive and provided meaningful clarity on the regulatory pathway for RAD101, reinforcing our confidence in the program’s potential to address a significant unmet need in brain metastases imaging. We are encouraged by the collaborative dialogue with the Agency and believe this interaction positions us well as we finalize our pivotal development strategy and take the next critical steps toward a potential registration program.”

Building on the momentum from the meeting, RAD is moving immediately to advance Phase 3 readiness activities, including clinical and operational planning, in order that the program is positioned to progress efficiently once the Agency’s formal feedback is received.

“RAD101 represents a differentiated imaging approach targeting fatty acid synthase, a compelling biological mechanism that has demonstrated promising clinical potential in brain metastases,” continued Mr. Canevari. “As we prepare for pivotal development, we are also evaluating opportunities to engage with potential strategic partners who recognize the value of this program and share our vision for bringing this innovation to patients and clinicians worldwide. Given the scale of the opportunity and the maturity of the asset, we believe now is the appropriate time to explore pathways that could maximize both clinical impact and long-term value creation.”

RAD101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company also recently announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support Radiopharm’s upcoming Phase 3 registrational trial in the U.S.

In the U.S. alone, there are more than 300,000 patients diagnosed annually with cerebral metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in systemic therapy resulting in a more durable control of the Primary tumor. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimize patient care.¹ 

About RAD101

RAD101 is the Company’s novel imaging small molecule that selectively binds to fatty acid synthase (FASN), a multi-enzyme protein that catalyses de-novo fatty acid synthesis and is overexpressed in cerebral metastasis from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College of London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may potentially represent a non-invasive prediction of overall-survival, warranting larger studies.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. Learn more at radiopharmtheranostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements regarding the planned development of RAD101, potential future clinical trials, regulatory interactions, Phase 3 readiness activities, a potential NDA submission, and potential strategic partnering opportunities. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. RAD101 is an investigational product and has not been approved for commercial use by the FDA or any other regulatory authority.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media:

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

¹ A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport | European Journal of Nuclear Medicine and Molecular Imaging

Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research

Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027

PRINCETON, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appointment of Matt Eckler, Ph.D., to its Board of Directors (the “Board”). Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets and scientific research in molecular biology and neuroscience.

“Matt brings deep understanding of the biotechnology sector, including extensive healthcare investment experience,” said Laurie Stelzer, Chair of the Board. “We look forward to his strategic insight and contributions as we advance rezatapopt toward potential commercialization and position PMV Pharma for continued growth and success.”

Dr. Eckler joins the Board following completion of enrollment in the Phase 2 monotherapy portion of the ongoing PYNNACLE Phase 2 pivotal clinical trial and as the Company prepares to submit a New Drug Application (NDA) for accelerated approval for rezatapopt in patients with platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation in the first quarter of 2027.

Rezatapopt is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

“I am pleased to join PMV Pharma’s Board at such an important point in its development,” said Dr. Eckler. “Rezatapopt represents a differentiated approach to targeting mutant p53, with the potential to address a significant unmet need for patients with difficult-to-treat cancers. I’m excited to collaborate closely with the Board and management team to help guide the Company through this next phase of growth and unlock the potential of its transformative science.”

Dr. Eckler is a Principal at Samsara BioCapital where he leads the firm’s public equity strategy. Before joining Samsara in 2025, he held investment roles at ArrowMark Partners, and GMT Capital, and served as Vice President and Senior Biotech Analyst at RBC Capital Markets. Earlier in his career, he conducted research on the genetics of early brain development and circuit-level plasticity.

He received a B.S. in biology from the University of North Carolina at Chapel Hill and a Ph.D. in molecular biology from the University of California (UC), Santa Cruz. Dr. Eckler completed his postdoctoral work in neuroscience at UC San Diego.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for rezatapopt, including our ability to obtain approval as a treatment option as a monotherapy, expectations regarding timing and success of the Phase 2 portion of the current clinical trial for rezatapopt and filing of a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities, including the successful filing of NDAs, and planned clinical trials, the Company’s ability to execute on its strategy and operate as a clinical stage company, the potential for clinical trials of rezatapopt or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, maintenance by the Company of ODD status and related benefits for rezatapopt, the Company’s ability to fund operations, and the impact that a global pandemic, other public health emergencies or geopolitical tensions or conflicts may have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026, and the Company’s other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts

Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com

Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com

Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potential

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has commissioned Lonquist Field Service (Canada), ULC (“Lonquist”) to conduct a desktop geological study to evaluate the potential for naturally occurring hydrogen and helium at its 100%-owned Robinsons River Salt Project in Newfoundland and Labrador.

The study will review existing geological, geophysical, and well data and compare the data against the expected conditions for potential hydrogen and/or helium generation, migration and trapping. Lonquist will evaluate the available information and recommend further investigation where warranted, providing a basis for the Company to determine its next steps. Vortex will provide an update following completion and review of the study.

“We want to make appropriate use of the information already available at Robinsons River,” said Paul Sparkes, Chief Executive Officer of Vortex Energy. “Lonquist’s review will help us determine whether natural hydrogen and helium warrant further exploration and where follow-up work could be most useful.”

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., Vice President of Exploration of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For additional information concerning the Project and the Company’s data-verification and quality-assurance procedures, readers are referred to the Company’s technical report entitled Independent Technical Report on the Robinsons River Salt Property, dated July 31, 2023, available under the Company’s profile on SEDAR+.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinsons River Salt Project, located approximately 35 kilometres south of the town of Stephenville in the Province of Newfoundland and Labrador. The Robinsons River Salt Project is prospective for salt and potential hydrogen storage in salt caverns. The Company has also acquired the Meadows Project, comprising approximately 21,609 hectares across 338 Crown parcels in west-central Saskatchewan near the Alberta border, which it intends to explore for salt with potential applications for compressed air energy storage and hydrogen storage. In addition, the Company holds its Fire Eye Uranium Property in the Wollaston Domain of northern Saskatchewan.

On Behalf of the Board of Directors

Paul Sparkes

Chief Executive Officer, Director

+1 (778) 819-0164

info@vortexenergycorp.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current beliefs or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the scope, conduct and completion of the desktop study by Lonquist; the potential for naturally occurring hydrogen and helium at the Robinsons River Salt Project; any recommendations arising from the study; the Company’s determination of next steps and any further exploration; and the Company’s intention to provide an update following completion and review of the study.

Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including, in respect of the forward-looking information included in this press release, assumptions that Lonquist will complete the study as contemplated; that the existing geological, geophysical and well data are sufficient and reliable for the purposes of the study; and that the Company will have the resources to carry out any follow-up work it determines to be warranted.

Although forward-looking information is based on the reasonable assumptions of the Company’s management, there can be no assurance that any forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among other things, the risk that the study is not completed on the timeline currently contemplated, or at all; that historical and third-party data relied upon in the study may be incomplete, inaccurate or not indicative of subsurface conditions; that the study may not identify conditions favourable to hydrogen or helium generation, migration or trapping, or may not support further investigation; that a desktop study does not establish the presence, quantity or recoverability of any hydrogen or helium; that the Company may be unable to obtain financing, permits or approvals for any follow-up work; risks inherent in the exploration of mineral properties and natural gas resources; and other factors beyond the Company’s control, including geological conditions. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.